Interrelations of lead levels in bone, venous blood, and umbilical cord blood with exogenous lead exposure through maternal plasma lead in peripartum women. by Chuang, H Y et al.
Environmental Health Perspectives • VOLUME 109 | NUMBER 5 | May 2001 527
Interrelations of Lead Levels in Bone, Venous Blood, and Umbilical Cord
Blood with Exogenous Lead Exposure through Maternal Plasma Lead in
Peripartum Women
Hung-Yi Chuang,1,2 Joel Schwartz,1,3 Teresa Gonzales-Cossio,4 Marlene Cortez Lugo,4,5 Eduardo Palazuelos,5
Antonio Aro,1,3 Howard Hu,1,3 and Mauricio Hernandez-Avila4,6
1Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA; 2Department of Occupational
Medicine, Kaohsiung Medical University Hospital, Taiwan; 3Channing Laboratory, Department of Medicine, Brigham and Women’s
Hospital and Harvard Medical School, Boston, Massachusetts, USA; 4Centro de Investigaciones en Salud Poblacional, Instituto Nacional
de Salud Publica, Cuernavaca, Morelos, Mexico; 5American British Cowdray Hospital, Mexico; 6Department of Environmental and
Occupational Health, The Rollins School of Public Health, Emory University, Atlanta, Georgia, USA
Lead is a well-known human reproductive
toxin. For centuries, lead exposure has been
linked to adverse outcomes in pregnant
women and newborns (1). In addition, fetal
lead exposure can cause delay in the embry-
onic development of multiple organ systems,
including retardation of cognitive develop-
ment in early childhood (2). 
Most studies that have used biomarkers
to measure fetal lead exposure have relied on
lead levels in maternal blood or umbilical
cord blood at birth. However, recent research
has cast doubt on whether either of these bio-
markers reﬂects fetal lead exposure in a way
that adequately predicts fetal lead toxicity.
For example, in a recent epidemiologic study
of women environmentally exposed to lead
in Mexico City, maternal bone lead levels
(but not maternal blood lead or umbilical
cord blood lead levels) were related to
declines in infant birth weight (3). In a com-
panion study, maternal bone lead levels (but
not maternal blood lead or umbilical cord
blood lead levels) were related to smaller head
circumference and shorter length at birth (4).
What parameters govern fetal lead expo-
sure, and why is maternal bone lead the best
predictor of fetal toxicity? Theoretically, fetal
lead exposure must involve lead that is avail-
able to cross the placenta. Lead that is free to
cross the placenta, in turn, must be derived
from lead in plasma. Within the circulatory
compartment, lead is partitioned primarily
between red cells (> 99%) and plasma (<
1%). Because most lead is bound to red
cells, whole blood lead levels (the biomarker
most commonly measured) invariably reﬂect
red-cell lead concentrations. However, the
lead that segregates into red cells is bound
and unavailable. If the < 1% of lead that is
found in plasma were always in equilibrium
with red-cell lead levels, whole blood lead
would serve as an adequate proxy for plasma
lead levels. However, recent research suggests
that plasma lead levels can vary substantially
without corresponding variations in whole
blood lead levels (5). For example,
Hernandez-Avila et al. (6) directly measured
plasma lead among environmentally exposed
adults in Mexico City and found that the
plasma:whole blood lead ratio varied
between 0.27% and 0.7%. In multivariate
analyses, bone lead levels were found to
inﬂuence plasma lead levels independent of
the effect of whole blood lead levels. The
strong inﬂuence of bone lead on plasma lead
probably reﬂects the role of bone as the main
repository (> 95%) of lead in adults (5). As
further evidence of the importance of bone
as a source of circulating lead, Gulson et al.
(7,8) conducted a series of studies of women
who had emigrated from Eastern Europe to
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Articles
Recent research has raised the possibility that fetal lead exposure is not estimated adequately by
measuring lead content in maternal whole blood lead because of the variable partitioning of lead in
whole blood between plasma and red blood cells. Lead in maternal plasma may derive in large part
from maternal bone lead stores. In this study we aimed to estimate the contribution of maternal
whole blood lead, maternal bone lead levels, and environmental lead to umbilical cord blood lead
levels (as a measure of fetal lead exposure). In the model, we assumed that lead from all of these
sources reaches the fetus through the maternal plasma lead pathway. In 1994–1995, we recruited
615 pregnant women for a study of lead exposure and reproductive outcomes in Mexico City. We
gathered maternal and umbilical cord blood samples within 12 hr of each infant’s delivery and
measured maternal lead levels in cortical bone and trabecular bone by a K-X-ray fluorescence
(K-XRF) instrument within 1 month after delivery. We administered a questionnaire to assess use
of lead-glazed ceramics (LGC) to cook food and we obtained data on regional air lead levels during
the 2 months before delivery. We used structural equation models (SEMs) to estimate plasma lead
as the unmeasured (latent) variable and to quantify the interrelations of plasma lead, the other lead
biomarkers, and environmental lead exposure. In the SEM analysis, a model that allowed plasma
lead to vary freely from whole blood lead explained the variance of cord blood lead (as reﬂected by
a total model R2; R2 = 0.79) better than did a model without plasma lead (r 2 = 0.67). Cortical
bone lead, trabecular bone lead, use of LGC, and mean air lead level contributed signiﬁcantly to
plasma lead. The exchange of lead between plasma and red blood cells was mostly in the direction
of plasma to cells. According to the ﬁnal model, an increase in trabecular bone lead and cortical
bone lead was associated with increases in cord blood lead of 0.65 and 0.25 µg/dL, respectively. An
increase of 0.1 µg/m3 in air lead was associated with an increase in the mean level of fetal cord
blood lead by 0.67 µg/dL. With one additional day of LCG use per week in the peripartum period,
the mean fetal blood lead level increased by 0.27 µg/dL. Our analyses suggested that maternal
plasma lead varies independently from maternal whole blood lead and that the greatest inﬂuences
on maternal plasma lead are maternal bone lead stores, air lead exposures, and recent cooking with
LGC. The contributions from endogenous (bone) and exogenous (environmental) sources were rel-
atively equal. Measurement of plasma and bone lead may be important in accurately assessing fetal
lead exposure and its major sources, particularly if exogenous exposures decline. Key words: blood
lead, bone lead, cord blood lead, maternal lead exposure, newborns, plasma lead. Environ Health
Perspect 109:527–532 (2001). [Online 11 May 2001]
http://ehpnet1.niehs.nih.gov/docs/2001/109p527-532chuang/abstract.htmlArticles • Chuang et al.
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Australia. In these women, the lead stored in
bone was a different isotopic ratio than lead
in their current environments. The investi-
gators demonstrated that pregnancy and lac-
tation were associated with large increases in
the amounts of lead released from bone. 
Together, these ﬁndings suggest that fetal
lead exposure, reﬂected by plasma lead levels,
may not be represented adequately by mater-
nal whole blood lead levels and that the
importance of bone lead levels as an indepen-
dent determinant of fetal lead toxicity may be
explained by the importance of bone lead as a
source of circulating lead and by its inﬂuence
on lead liberated into plasma. 
What factors inﬂuence plasma lead levels
during pregnancy, and why not simply mea-
sure plasma lead levels? Unfortunately, direct
measurement of lead in plasma is an extraor-
dinarily challenging procedure because of sev-
eral factors. Among the most important are
the potential for plasma lead to be signifi-
cantly contaminated by lead in red blood cells
with even a small amount of hemolysis; the
extremely low levels of lead in plasma (< 0.1
µg/dL), which can be measured precisely and
accurately but requires special instruments;
and the potential for environmental contami-
nation from equipment and from other
sources during phlebotomy, specimen trans-
ports, digestion procedures, and analysis.
As a consequence, few studies have inves-
tigated plasma lead levels, and, to the best of
our knowledge, none has done so during
pregnancy. Because umbilical cord blood
lead levels are the best available measure of
fetal lead exposure and because plasma lead
must be the vehicle for both exogenous (envi-
ronmental) and endogenous (bone) sources
of lead that inﬂuence fetal lead exposure, the
role of plasma lead in fetal lead exposure can
be investigated directly by examining interre-
lationships between existing biomarkers of
lead exposure and assuming that cord blood
lead is inﬂuenced most by plasma lead. 
The aim of the current study was to use
data from a large epidemiologic study (n >
600) of lead and reproduction and to apply
structural equation models (SEMs) to esti-
mate the effects of endogenous and exoge-
nous lead exposure on fetal cord blood lead
through maternal plasma lead. The women
who participated in this study live in Mexico
City, where environmental lead exposure
and consequently bone lead levels have been
high (9). Measurements were available for
environmental sources of lead exposure and
levels of lead in maternal whole blood,
maternal trabecular and cortical bone, and
umbilical cord blood.
Materials and Methods
Study subjects. From 28 April 1994 to 30
June 1995, women attending any of three
hospitals (Mexican Social Security Institute,
Manuel Gea Gonzalez Hospital, or National
Institute of Perinatology) for prepartum
examination in Mexico City were recruited.
Interviewers explained the study in detail and
obtained informed consent from participants.
The study protocol was approved by the
Human Subjects Committee of the National
Institute of Public Health (Mexico City,
Mexico). Women were excluded if they had a
physician’s diagnosis of multiple fetuses,
preeclampsia, psychiatric, kidney or cardiac
diseases, gestational diabetes, history of
repeated urinary infections, seizure disorder
requiring daily medication, ingestion of corti-
coids, systolic blood pressure > 140 mm Hg,
or diastolic blood pressure > 90 mm Hg. 
Maternal and umbilical cord blood lead
test. Maternal and umbilical cord blood sam-
ples were gathered within 12 hr of each
infant’s delivery. Blood samples were analyzed
by atomic absorption spectrometry (Perkin-
Elmer 3000; PerkinElmer, Norwalk, CT,
USA) at the metal laboratory of the American
British Cowdray Hospital in Mexico City.
Analyses of external blinded quality-control
samples were provided throughout the study
period by the Wisconsin State Laboratory of
Hygiene (WSLH) Cooperative Blood Lead
Proficiency Testing Program (PBPTP)
(Madison, WI, USA). On tests of blinded
specimens in the ranges of 0–8, 14–22, and
40–50 µg/dL, the laboratory performed with
accuracy within 5.0% and a coefficient of
variation (CV) < 15%, which demonstrated
good precision and accuracy of the determi-
nations made at American British Cowdray
Hospital.
Bone lead test. At each mother’s visit to
the research center at American British
Cowdray Hospital 1 month after delivery,
maternal bone lead levels were measured on
each woman’s mid-tibia shaft (cortical) and
patella (trabecular) with a spot-source 109Cd
K-XRF instrument (ABIOMED Inc.,
Danvers, MA, USA). Thirty-minute mea-
surements were taken at each bone site after
the skin had been washed with 50% iso-
propyl alcohol. The K-XRF beam collimator
was sited perpendicular to the bone surface
for the tibia and 30° in the lateral direction
for the patella. The introduction of 109Cd as
an excitation γ -ray source, with 88 keV pho-
tons emitted from approximately 4% of its
decays, provokes the emission of ﬂuorescent
photons from the target. The resulting signal
sensed by the detector, high-puriﬁed germa-
nium crystal, undergoes processing by the
amplifier-computer system for subsequent
display and analysis. The detection system
collects, counts, and analyzes the emitted X-
rays over the wavelength spectrum, from
which the net lead signal is determined after
subtraction of Compton background counts,
by a linear least-square algorithm. The lead
ﬂuorescence signal is then normalized to the
elastic or coherently scattered γ -ray signal,
which arises predominantly from the calcium
and phosphorus present in bone mineral.
The unit of measurement is micrograms per
gram (µg/g) of bone mineral (10). Because
the K-XRF instrument provides a continu-
ous, unbiased estimate that oscillates around
the true bone lead value, negative value esti-
mates are sometimes produced when true
bone lead values are close to zero. The instru-
ment also provides an estimate of uncertainty
association with each measurement, which is
derived from a goodness-of-ﬁt calculation of
the spectrum curve and is equivalent to a sin-
gle standard deviation. Although a minimal
detectable limit calculation of twice this value
has been proposed for interpreting an indi-
vidual’s bone lead estimates, statistical experi-
ments have shown that retention of all point
estimates makes better use of the data in epi-
demiologic studies (11,12). Validation stud-
ies of the instrument indicated a high degree
of precision and accuracy of point estimate
and uncertainty measurement in comparison
with chemical analysis in studies of lead-
doped phantoms (13).
Use of lead-glazed ceramics. Previous
studies have shown that use of low-tempera-
ture–fired lead-glazed ceramics (LGC) is a
major source of lead exposure in Mexico
City (15,19). To evaluate this exposure, we
interviewed participants in the research
ofﬁce by trained personnel using a structured
questionnaire. Using pictures to help iden-
tify these LGC, we asked participants about
the frequency of LGC use in the previous
week (number of days used per week) and
about the number of years they had used
LGC to store and cook food. The product of
these two variables was used to estimate the
total lifetime days of LGC use:
Air lead concentrations. We used the air
lead data supplied by the Environmental Air
Monitoring Network of Mexico City.
Nineteen monitoring points in Mexico City
provide information on air lead levels, which
were measured four to ﬁve times per month.
We used information regarding the area of
residency of participants and assigned these
data to subjects depending on their area of
residence and the date of delivery. The mean
of air lead levels for the previous 2 months
before delivery was the index of lead
exposure from ambient air for each woman.
In addition, we used the number of years of
residence in Mexico City to indicate chronic
exposure. 
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.Estimated lead in red blood cells.
Because < 1% of lead is present in plasma
(6,16), we used whole blood lead level
divided by hematocrit (BPb/Hct) to estimate
lead concentration in red blood cells (RBC).
Out calculation is:
Data analysis. Descriptive statistics. We
examined univariate distributions of contin-
uous variables to determine the normality of
the variables. To better attain normal distri-
butions, maternal and cord blood lead values
were natural log-transformed. Outliers were
identified using the extreme studentized
deviate (ESD) procedure (17). Percentiles
for the procedure are approximated on the
basis of the t-distribution (18,19). To assess
the potential influence of outliers, we
repeated our SEM analyses after excluding
four outliers. We used Pearson correlation
analyses to determine the intercorrelations
among the lead biomarkers (maternal whole
blood and bone lead levels, umbilical cord
blood lead level) and use of LGC, air lead
levels, maternal age, and time of residence in
Mexico City in both years and percentage of
life span spent in Mexico City (years of resi-
dence in Mexico City divided by age).
Multiple regression analyses. As predic-
tors of fetal cord blood lead levels, the inde-
pendent inﬂuence of age, our maternal lead
biomarkers, and our external exposure para-
meters, including use of LGC, air lead levels,
and percentage of life span in Mexico City,
were examined. 
Structural equation models. SEMs were
used to express the relationships among vari-
ables, including measured variables and
plasma lead (latent variable) (20), and thus to
test the hypothesis that maternal bone lead
levels contribute to fetal lead exposure inde-
pendent of maternal whole blood lead levels.
Structural equation modeling allows one to
estimate simultaneously a set of interrelated
regression models. For example, bone lead
must be considered an outcome in one
regression (depending on use of LGC, length
of residence in Mexico City, and the like). In
a second regression model it is a predictor of
umbilical cord lead. By combining these into
one system of equations, one gains several
advantages. First, estimates may be made
more precisely, taking into account the
covariance structure of all of the variables.
Second, downward bias that results from
putting variables on the casual pathway into
the regression (21) may be avoided. Third,
the system of equations may be compactly
written in terms of a path diagram that illus-
trates the multiple relationships. Finally,
unmeasured (latent) variables may be
included when there is sufficient ancillary
information. While this produces noisy esti-
mates of the latent variable, recognizing its
existence usually increases the precision of
the estimates of the associations among the
measured variables. These models have been
well developed and described since the
1960s. Our analysis approach conceptualizes
plasma lead levels as the unmeasured,
“latent” variable through which lead levels in
the maternal patella, tibia, and venous blood
can inﬂuence umbilical cord blood lead levels
(as fetal lead exposure). 
To ﬁt our model, we established the net-
work of causal relationships among the vari-
ables (Figure 1). The direction of causality
among these variables is clear. All that is
unknown is the magnitude of the associa-
tions (which for some pathways may be
zero). As a second step, we constructed a
structural model with a latent variable
plasma lead level added. This allowed us to
test the hypothesis that such a model ﬁt the
data better and that some variables may
influence cord lead through plasma rather
than erythrocyte lead. We used the covari-
ance analysis of linear structural (CALIS)
equation in SAS package 6.12 (CALIS pro-
cedure; SAS Institute Inc., Cary, NC) for
SEM analysis (22). All these analyses used
the maximum likelihood method of parame-
ter estimation, and all were performed on
the variance–covariance matrix (20).
We assumed that missing data occurred
completely at random (MCAR). Missing data
were the result of incomplete questionnaires
and incomplete collection of blood samples.
The most common reasons for failure to col-
lect blood samples and questionnaires were
inconvenience and the time-consuming
nature of the interview process. In the data
analysis, we used the pairwise deletion
method to treat missing data; each correla-
tion and covariance between two variables
was computed from pairwise-complete data,
with the exclusion of cases that had missing
values for one or both variables (23,24). 
Results
A total of 615 pregnant women had bone
lead measurements. The most common rea-
son for which women did not have bone
lead measurements were residence outside
Mexico City and the length of time required
for the measurement. Table 1 shows the
characteristics of study subjects. Bone lead
levels were considered missing if they were
associated with excessive measurement
uncertainty (> 15 µg/g in patella and > 10
µg/g in tibia) reflecting quality assurance
procedures used previously (11,25). Thus,
only 575 women had patella lead levels and
603 had tibia lead levels; the mean (SD) val-
ues for the patella and tibia lead values were
14.24 (14.19) and 9.67 (9.21) µg/g bone
mineral, respectively, and 86 (14%) and 78
(13%) of these values, respectively, were 0 or
negative, signifying very low levels measured
with error. Among the women who used
LGC for cooking, 25% reported using LGC
≤ 3 day per week and 8% reported use ≥ 3
days per week (mean 2.92 days per week, SD
= 2.28). About 20% of the women had used
LGC for ≤ 5 years and 16% of the women
for ≥ 5 years (mean 9.03 years, SD = 9.13).
The mean number of days of lifetime LGC
use, calculated from the above variables, was
1,489 (SD = 2,010). Twenty-six women
(4%) reported smoking during pregnancy;
about 39% had smoked in the past but not
during pregnancy.
Table 2 shows the Pearson correlation
coefficient matrix. Natural log-transformed
cord blood level was signiﬁcantly correlated
with all maternal lead biomarkers, use of
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Figure 1. Manifest model of interrelationships of bone lead and umbilical cord blood lead in peripartum
women. Standardized coefﬁcients are presented. 
*p < 0.05.
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Cord blood
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of ceramics
to cook
Mean of air
lead in the
2 monthsLGC, air lead level, and years of residence in
Mexico City. Number of years living in
Mexico City was signiﬁcantly correlated with
age (R2 coefficient = 0.45). To avoid
collinearity between these two variables, we
used percentage of life span spent in Mexico
City, which did not correlate with age (R2
coefﬁcient = –0.057, p = 0.159). Few women
reported smoking while pregnant (n = 26).
Neither current nor past smoking was associ-
ated with any of the lead biomarkers. Thus,
we did not include smoking status in further
analyses. 
In a multiple regression analysis (data
not shown), maternal blood lead level was
highly associated with fetal cord blood lead
level. Maternal tibia lead level, patella lead
level, and the other exposure indices (includ-
ing LGC use, air lead level, and percentage
of life span in Mexico City) were not signiﬁ-
cantly associated with cord blood lead levels.
However, as discussed by Breslow and Day
(21), this regression analysis was inappropri-
ate because maternal blood lead was an
intermediate marker for sources of lead
exposure, (i.e., maternal blood lead level was
inﬂuenced by bone lead and external sources
of lead exposure). Failure to account for
these interrelationships weakened the analy-
sis. Thus, we used SEMs to assess the inter-
relationships of these factors.
Figures 1 and 2 depict the results
obtained in SEMs without and with the
plasma lead level respectively. The coeffi-
cients in these two ﬁgures were standardized
to represent a 1 SD change in each exposure
pathway. In testing for overall model ﬁts, we
found the goodness-of-fit index (GFI) and
degree-of-freedom–adjusted GFI in both
models were ≥ 0.9 (1 = perfect ﬁt). In both
models, Bentler’s comparative fit indices
were ≥ 0.95 (1 = perfect ﬁt). All indices for
model fit revealed an acceptable fit in both
models (20). The SEM used for the analysis
shown in Figure 1 revealed that both cortical
and trabecular bone lead levels signiﬁcantly
contributed lead to the maternal blood pool
in pregnant women. The lead in patella (tra-
becular bone) contributed more than that in
tibia (cortical bone). Long-term use and
recent use of LGC were positively correlated
with bone and blood lead levels, respectively.
However, air lead levels measured 2 months
before delivery were only weakly associated
with whole blood lead in the model. Overall,
the coefﬁcient of maternal whole blood lead
to cord blood lead was similar to the regres-
sion coefﬁcient and explained about 67% of
variance in the cord blood lead level.
In the model used for the analysis in
Figure 2, we implanted a latent variable,
plasma lead, and RBC lead to represent two
components in the blood pool. First, we
observed that both bone lead measures con-
tributed signiﬁcantly to maternal plasma lead.
Second, we found that recent air lead level
was signiﬁcantly associated with plasma lead
but not with whole blood lead. To compare
the coefficients in the different models, we
standardized them to represent a 1 SD change
in each blood index. The standardized coefﬁ-
cient for whole blood lead level was 0.8203
whereas that for plasma lead level was 0.8897.
On the other hand, the R2 values were 0.792
in the plasma model and 0.673 in the whole
blood model. Both results suggest that plasma
lead affects fetal cord blood lead stronger than
maternal whole blood lead level.
Table 3 shows estimates of fetal cord
blood changes, calculated from the ﬁnal SEM
in Figure 2 with use of nonstandardized coef-
ﬁcients (original or natural coefﬁcients) and
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Table 1. Characteristics of study subjects.
Variable No.  subjectsa Mean (SD) or %
Maternal blood lead, µg/dL  608 8.45 (3.94)
Maternal hematocrit  604 0.41 (0.04)
Estimated RBC lead  597 20.59 (9.54)
Umbilical cord blood lead, µg/dL  509 6.55 (3.45)
Patella lead, µg/g bone mineral  575 14.24 (14.19)
Tibia lead, µg/g bone mineral  603 9.67 (9.21)
Maternal age, year  614 24.52 (5.11)
Residence in Mexico City, year  613 20.57 (8.23)
Residence in Mexico City, % of life span  613 84.22 (29.55)
Air lead 2 months before delivery, µg/m3 522 0.21 (0.02)
Current smoker 26 4.2%
Ex-smoker 242 39.3%
Cooking in LGC in the week before delivery
No 406 66.0%
1–3 days/week 154 25.0%
4–7 days/week 49 8.0%
Unknown 6 1.0%
Cooking in LGC in lifetime 
No 354 57.6%
≤ 5 years 122 19.8%
6–10 years 36 5.9%
11–15 years 8 1.3%
> 15 years 53 8.6%
Unknown 42 6.8%
aThe numbers are not consistent because of missing data.
Table 2. Correlation coefﬁcient matrix for lead biomarkers, use of LGC, age, residence in Mexico City, and smoking status.
Log Time P_Y
MPB Pat Tibia Age Cook PbAir Mex Mex Day Year Smoke
LogCPB 0.82 0.23 0.18 0.08 0.15 0.10 0.12 0.07 0.21 0.20 0.05
p-Value 0.0001 0.0001 0.0001 0.0638 0.0011 0.0404 0.0072 0.1045 0.0001 0.0001 0.2601
n 506 472 498 508 468 440 507 507 503 471 508
LogMPB 0.2232 0.1493 0.0473 0.1864 0.0417 0.1290 0.1184 0.2336 0.2167 0.02866
p-Value 0.0001 0.0003 0.2451 0.0001 0.3431 0.0015 0.0035 0.0001 0.0001 0.4810
n 569 596 607 565 518 606 606 602 568 607
Pat 0.2630 0.1240 0.0910 0.0082 0.1830 0.1287 0.1420 0.0702 0.0659
p-Value 0.0001 0.0029 0.0360 0.8571 0.0001 0.0020 0.0007 0.1052 0.1148
n 564 574 531 488 573 573 569 534 574
Tibia 0.1645 0.1200 –0.0550 0.2441 0.1816 0.1444 0.1129 0.0593
p-Value 0.0001 0.0045 0.2127 0.0001 0.0001 0.0004 0.0075 0.1461
n 602 558 515 601 601 597 561 602
Age 0.0506 –0.0913 0.4547 –0.0569 0.0241 0.0861 0.04342
p-Value 0.2280 0.0373 0.0001 0.1594 0.5526 0.0393 0.2828
n 570 521 613 613 609 573 614
Abbreviations: LogCPB, natural log-transformed cord blood lead; LogMPB, natural log-transformed maternal blood lead; Pat, patella lead; Tibia, tibia lead; Cook, total lifetime days of
cooking with lead-glazed ceramics; PbAir, mean of air lead 2 months before delivery; TimeMex, years living in Mexico City; P_Y Mex, percentage of life span in Mexico City; Day, days of
cooking with lead-glazed ceramics per week; Year, years of cooking with lead-glazed ceramics in lifetime; Smoke, smoking or not during pregnancy.an antilogarithmic calculation method (cord
blood lead level, maternal blood lead level,
and RBC lead level were log-transformed in
the models). According to these estimates, an
increase of 1 µg/g in maternal patella lead
was associated with an increase in mean level
of fetal cord blood lead by 0.032 µg/dL. An
increase in maternal patella lead from the ﬁrst
quartile (4.26 µg/g) to the third quartile
(23.71 µg/g) was associated with an increase
in mean level of cord blood lead by 0.65
µg/dL. The contribution from tibia (cortical
bone) was a little less than that from patella
(trabecular bone). An interquartile range
change in both bone lead measures was asso-
ciated with an increase in cord blood lead by
about 1 µg/dL. One additional day of LGC
use per week in the peripartum period was
associated with an increase in mean level of
fetal blood lead by 0.27 µg/dL. Fetal blood
lead was also inﬂuenced by air lead levels in
peripartum period: Each 0.1 µg/m3 change
in air lead was associated with a 0.67 µg/dL
change in mean level of fetal cord blood lead.
As a plausibility check on this model, we
note that Crocetti et al. (26) showed that
gasoline use contributed to about 9 µg/dL
of blood lead levels in U.S. children in
1976, a time when air lead concentrations
in U.S. urban areas were typically 1–1.25
µg/m3, a result quite consistent with the air
lead–blood lead ratio we see.
Discussion
Our study suggests that incorporating
plasma lead as a latent variable in models
used to analyze the relationship of bone lead
and exogenous lead exposure with cord
blood lead reveals important relationships.
In our analysis with SEMs, maternal plasma
lead level had a stronger association (stan-
dardized coefficient = 0.8897) than that of
whole blood lead (standardized coefﬁcient =
0.8203) to fetal cord blood lead level, and
the fit of the model that incorporated
plasma lead (R2 = 79%; Figure 2) was sub-
stantially better than the fit of the model
that omitted plasma lead (R2 = 67%; Figure
1). Moreover, the model demonstrated a
significant contribution of lead from the
skeletal system to plasma during pregnancy,
a contribution that is independent of the
influence of maternal RBC lead. One can
infer that plasma lead is an important bio-
marker for fetal lead exposure and that
maternal whole blood lead levels do not
accurately capture the inﬂuence of bone lead
on fetal lead exposure. Use of a biologically
plausible model for the pathways of lead
kinetics greatly increased our ability to sepa-
rate out the contributions from different
sources. For example, lead in both cortical
and trabecular bones was released into
blood during pregnancy. In a standard mul-
tiple regression analysis, we cannot easily
separate the contribution from each path-
way to maternal blood lead level and study
their effects on fetal cord blood lead by way
of maternal blood or plasma lead levels
because of correlation and collinearity
between patella and tibia lead levels.
Four sources of lead contributed signiﬁ-
cantly to plasma lead. Recent use of LGC and
lead in trabecular bone (patella) had the largest
and the second largest standardized coeffi-
cients, respectively—results indicating that
these two sources had the greatest inﬂuence on
plasma lead levels. The greater contribution of
trabecular than of cortical bone probably
reflects the greater vascularity and higher
turnover rate of trabecular bones. Use of LGC,
a documented source of lead exposure in
women and children in Mexico City (15), was
a source of food contamination and a path of
lead ingestion in this study; lead absorbed by
the gastrointestinal tract is quickly detectable
in the plasma. The standardized coefﬁcient for
air lead level was the smallest of these four
pathways, but this ﬁnding was in part a reﬂec-
tion of the relatively narrow distribution of air
lead levels to which these women were
exposed, which, in turn, is a reﬂection of the
effort in Mexico over the last 10 years to phase
out the use of leaded gasoline. Using original
coefﬁcients (normal scale) of SEM in Figure 2,
a change of 0.1 µg/m3 in air lead level would
have a sizable effect on fetal cord blood lead
level (0.67 µg/dL). 
The effect of RBC lead on plasma lead
detected in our model revealed that most lead
moved from plasma to RBC and less from
RBC to plasma. The coefﬁcient ratio of lead
movement into/out of RBC was about 6.
The kinetic equilibrium between RBC lead
and plasma lead has been studied previously
(7,27,28). Both Marcus (27) and deSilva
(28) demonstrated a nonlinear relationship
between plasma lead and blood lead with a
kinetic transfer ratio (into/out of RBC) rang-
ing from 214 to 373. Plots in these studies
revealed a J-shaped curve for plasma versus
blood lead. However, their analyses were on a
normal scale, while ours used natural loga-
rithm-transformed RBC and cord blood lead
levels. Exponentiation of our ratio gives a
value of 403, which is similar to the results
obtained by their investigations. Because we
log-transformed both variables, the shape of
the relationship in our model followed a
power law and incorporated much of the
nonlinearity in the models used by Marcus
and deSilva.
Recent studies with a lead isotope com-
position method have proved that maternal
skeletal lead is mobilized during pregnancy,
makes major contributions to the maternal
blood pool, and is transferred to the fetus
(7,8). In these studies, a higher 206Pb/204Pb
ratio reflected the abundance of the 206Pb
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Table 3. Changes in cord blood lead level associated with speciﬁed changes in endogenous and environ-
mental factors, according to the ﬁnal structural equation model with normal scale unit.
Variables Cord blood lead change (µg/dL)
Patella lead change
1 µg/g of bone mineral 0.032
Interquartile (4.26–23.71 µg/g of bone mineral) 0.65
Tibia lead change
1 µg/g of bone mineral 0.022
Interquartile (4.08–15.40 µg/g of bone mineral) 0.25
Cooking with LGC
1 day/week 0.27
Interquartile (1–3 days/week) 0.56
Air lead level change
0.1 µg/m3 0.67
Figure 2. Latent model of interrelationships of bone lead and umbilical cord blood lead in peripartum
women to estimate the effect of plasma lead. Standardized coefﬁcients are presented. 
*p < 0.05. 
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RBC leadisotope in the country where the women
grew up and was different from the isotopic
ratio (lower) in their current country of resi-
dence. The increased isotopic ratio in blood
when these women were pregnant reflected
the bone lead (with higher isotopic ratio)
released into blood. The skeletal contribution
of lead to blood lead level, based on Gulson’s
(30) study of nine pregnant immigrant
women, produced a mean increase of 31% in
the 206Pb/204Pb ratio (range, 9–65%). These
studies provided evidence for significant
increase of skeletal lead mobilization during
pregnancy. However, the amount of lead
contributed to plasma (i.e., the partitioning
of lead in the blood pool) was indirectly mea-
sured using unique samples (29). In addition,
only a small number of subjects were willing
to undergo tibial XRF measurements because
of concern over past radiation exposure (30). 
Multiple linear regression models may
not permit a full appreciation of the influ-
ence of maternal bone lead levels on the fetal
cord blood lead levels through maternal
blood or plasma lead levels, because they
involve the use of one dependent variable
and multiple independent variables in a sin-
gle equation. Because maternal blood lead is
an intermediate marker for the source of lead
exposure, the model may be overcontrolled
by the inclusion of all independent variables
with equal roles in the matrix (20). For
example, bone lead must be released into
maternal plasma to influence the fetal cord
blood lead levels; however, in a multiple
regression model, the inﬂuence of bone lead
levels on the fetal cord blood lead levels can-
not be revealed after controlling for maternal
blood lead. In the SEM, plasma lead can be
inserted as a latent variable in a set of relative
equations, and covariance matrix and maxi-
mal likelihood estimation can be used to cal-
culate coefﬁcients that indicate the association
between plasma lead and the other observed
variables. 
The results of our study suggest that
plasma lead level is an important biomarker
for endogenous and exogenous lead exposure
in pregnant women and their fetuses.
Insertion of plasma lead level as a latent vari-
able in the SEM allowed us to examine simul-
taneously the association between maternal
bone lead and external lead exposures on fetal
cord blood lead without bias. However, this
method cannot offer an actual plasma lead
value. Although currently difficult, plasma
lead measurement may be necessary to
elucidate particular lead toxicity issues, such
as the mobilization of lead from bone and
fetal lead exposure during pregnancy.
The results of our study also suggest that
if one wants to predict fetal lead exposure (as
signified by cord blood lead levels) before
pregnancy occurs, measuring maternal bone
lead levels as well as maternal blood lead lev-
els and current environmental sources of
lead exposure may provide a powerful set of
tools. Our analysis using cross-sectional epi-
demiologic data certainly has limitations from
a biokinetics point of view because we do not
have repeated measurements with which to
measure dynamic relationships and are unable
to glean from our data any immediate bioki-
netic relationships, such as those between fetal
RBC lead and fetal plasma lead. Moreover, a
simple cord blood lead level alone is likely to
have limited ability to represent fetal lead
exposure throughout pregnancy. Nevertheless,
from a clinical and epidemiologic point of
view, maternal bone and blood lead levels
and environmental data remain the only
tools available with which to assess individual
risks before or early in pregnancy. Such risk
assessments, in turn, are important, given the
attention that is now starting to be directed
toward developing strategies for preventing
maternal bone lead mobilization during preg-
nancy using approaches such as nutritional
supplementation (31).
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